Roth MKM raised the firm’s price target on Cellectar Biosciences to $28 from $20 and keeps a Buy rating on the shares. The firm cites the company’s Q4 results and updating indicating that its pivotal iopofosine 131I trial delivered strong efficacy and safety in highly refractory Waldenstrom’s macroglobulinemia patients, “handily beating” the required success. Iopofosine 131I is also showing benefit in several disease settings, making Cellectar Biosciences an attractive acquisition target, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Options Volatility and Implied Earnings Moves Today, March 27, 2024
- Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
- Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
- Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
- CLRB Upcoming Earnings Report: What to Expect?